Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Antibodies
Filter     Order     Display # 
Date Item Title
19 Mar 2008 MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
18 Mar 2008 Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
17 Mar 2008 Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
17 Mar 2008 MorphoSys Obtains Agreement for Production of Antibody Material in MOR202 Program with Crucell and DSM
16 Mar 2008 GlaxoSmithKline's Bosatria shows promise in late-stage study
13 Mar 2008 Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
12 Mar 2008 BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
12 Mar 2008 Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
11 Mar 2008 Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10 Mar 2008 iCo Therapeutics Provides iCo-008 Phase II Clinical Update
05 Mar 2008 Phase I/II Studies of IMC-A12 in Pediatric Cancer Patients Commence Enrollment
05 Mar 2008 Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
04 Mar 2008 UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
04 Mar 2008 Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
03 Mar 2008 BioWa Announces Expansion of License Agreement With Genetech for BioWa's POTELLIGENT(R) Technology
03 Mar 2008 Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
29 Feb 2008 Herceptin approved in Japan for early treatment in patients with HER2-positive breast cancer
27 Feb 2008 MorphoSys and Sigma-Aldrich Enter into a Collaboration and Licensing Agreement for Recombinant Research Antibodies
27 Feb 2008 FDA Approves Regeneron's ARCALYST(TM) (rilonacept) for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
26 Feb 2008 Bradmer announces phase ii results published in newly diagnosed Glioblastoma which demonstrate improved survival and support upcoming Phase III study
25 Feb 2008 ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery Via Eye Drops
22 Feb 2008 Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial
22 Feb 2008 FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
22 Feb 2008 Phase II Study of IMC-1121B for Advanced Liver Cancer Commences Patient Enrollment
22 Feb 2008 Abbott Receives FDA Approval for HUMIRA® (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
21 Feb 2008 Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma
21 Feb 2008 MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to Develop Novel Antibody Therapies
20 Feb 2008 Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss
19 Feb 2008 InNexus Biotechnology Announces Second Preclinical Candidate DXL702 (HER2/neu) Targeting Breast Cancer
19 Feb 2008 Biolex Therapeutics Enters Into Agreement With Merck KGaA for Antibody Optimization
18 Feb 2008 Takeda Discontinues Development of Matuzumab
18 Feb 2008 EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
13 Feb 2008 Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint
13 Feb 2008 YM BioSciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Caincer
13 Feb 2008 Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
12 Feb 2008 Sanofi-aventis enters into Antibody Agreements with Dyaxand "Phage Display Technology"
12 Feb 2008 MorphoSys Receives CTA Approval to Initiate Phase 1 Clinical Study for MOR103 Program
12 Feb 2008 Thallion Agrees with FDA on a Path Forward for Shigamabs Development Program in the U.S.
11 Feb 2008 2008 is a decisive year for the validation of the asthma target interleukin-13
11 Feb 2008 FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
08 Feb 2008 Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
08 Feb 2008 Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
07 Feb 2008 Human Genome Sciences and Xencor Announce Genoma Collaboration
07 Feb 2008 InNexus Biotechnology Announces Preliminary Results of Animal Study Comparing Cancer Killing Activity of Its DXL625 (CD20) Treatment for Non-Hodgkin’s Lymphoma With Leading Marketed Product
06 Feb 2008 Biovitrum and Symphogen have Successfully Completed Phase I Clinical Trial with Recombinant Polyclonal Antibody
06 Feb 2008 FDA Agrees to Review Cimzia® File for the Treatment of Rheumatoid Arthritis
06 Feb 2008 OctoPlus commences United States Phase IIa study with Locteron for the treatment of hepatitis C
05 Feb 2008 FDA Gives Green Light to Lpath's ASONEP(TM) IND Submittal
04 Feb 2008 MedImmune Submits Biologics License Application to FDA for Motavizumab
04 Feb 2008 Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 201 - 250 of 1063

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Toll-Like Receptor (TLR) Agonists & Antagonists

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics